Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 507 participants.

Also called NCT01201837

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 507 participants (enrolled count) (from the registry)
Sponsor
Cerenis Therapeutics, SA (from the registry)
Registry
  • NCT NCT01201837
Other papers using this trial's data
  • Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial European heart journal, 2014-12-07 DOI, PubMed 24780501, PMC4258222 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada, France, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01201837. Randomized; quadruple masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2012-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Acronym
CHI SQUARE
Condition
Acute Coronary Syndrome
Intervention (Drug)
Placebo
Intervention (Drug)
CER-001
Lead sponsor
Cerenis Therapeutics, SA (class: industry)

Record details

Record id
cardio:ct-nct01201837
Content hash
1cae2348ec7ad01db512899f97b658682c77941f2bf12561e292f75b8a318932